The Galien Forum USA 2019

PANEL
1

Chair
MaryAnne Rizk
Senior Vice President, Digital R&D Strategy
IQVIA

Panelists
Nancy Dreyer PhD, MPH, FISPE, Fellow DIA
Chief Scientific Officer
IQVIA

Emmanuel Fombu
Global Strategy and Digital Innovation Leader
Johnson & Johnson

Karl Hick
Chief Digital & Information Officer
Takeda

Jim Scholefield
Chief Information & Digital Officer
Merck

Panel Intro

Digital Health Transformation – Orchestrating patient-centricity from molecule to market


Chair
MaryAnne Rizk
Senior Vice President Digital R&D Strategy
IQVIA

Dr. MaryAnne Rizk has been a rising global digital technology life science executive for the past 20+ years, transforming the way the biopharmaceutical industry manages digital health to improve patient outcomes. Effective in building enterprise alliance programs, Dr. Rizk has forged clinical outsourcing collaborations to improve patient centricity across hundreds of global life science stakeholders across Pharma, Biotech, Medical Device through tech-enabled services via CROs. With a proven track record in the SaaS sales and marketing, Dr. Rizk has shaped high-performance teams, working cross-functionally to increasing customer value. She brings broad-based expertise in leading SaaS channel programs to support growth strategies and deliver profitable revenue under complex, dynamic market conditions.

At IQVIA, Dr. Rizk is responsible for driving the digital R&D transformation breakthroughs from molecule to market via the Orchestrated Clinical Trials (OCT) SaaS platform. The first of its kind end-to-end clinical technology platform leverages embedded intelligence, unparallel data, and analytics to trigger a series of orchestrated automation around patient-centric workflows and supporting trial automation to lead precision therapies to market smarter and faster competitively. Before IQVIA, MaryAnne has globally lead both Oracle and Medidata’s strategic channel partnership strategy to enables organizations to leverage innovative SaaS cloud-based platform technologies to accelerate drug/device development. Leveraging her systems engineering background, MaryAnne had started her career at Merck by leading the charge to retire legacy paper-based processes to gain operational excellence and earlier digital insights while adhering to patient-centric clinical care.  She’s spent time at the clinical site-level to engage in how data is being collected by clinicians and brought her insights back to coach and translate meaningful functionality required to the R&D engineering teams.

In additional to driving platform adoptions across several leading industry clinical solutions, she has been an advocate and trusted advisor to shape the emerging technology revolution of Big Data fueling AI, Machine Learning, and Blockchain adoption. MaryAnne is an accomplished speaker and has participated on over 30+ publications with industry peers and has spoken at 50+ industry sessions to continue to advocate the meaningful value of technology, translated into improved clinical patient care as well as satisfying significant business outcomes.

Dr. Rizk has received her Bachelor of Engineering and Masters in Technology Management from Stevens Institute of Technology. She also completed her Ph.D. in Technology Management, specializing her dissertation and research in Pharmaceutical Strategic Partnerships. Dr. Rizk holds various board, chair and leadership memberships and is a proud member of the following networks: Healthcare Businesswomen’s Association (HBA), New York Health Business Leaders (NYHBL), Drug Information Association (DIA), Society of Clinical Data Management (SCDM) and Society of Clinical Research (SCRS).


Nancy_Dreyer

Nancy Dreyer PhD, MPH, FISPE, Fellow DIA
Chief Scientific Officer
IQVIA

Nancy Dreyer is Chief Scientific Officer and Senior Vice President at IQVIA.  She focuses on generating real-world evidence for regulators, clinicians, patients and payers through pragmatic trials and non-interventional approaches and has more than 200 publications on real-world evidence, including the popular book, Registries for Evaluating Patient Outcomes: A User’s Guide, now in its 4th edition. She is also known for creating the GRACE Checklist, the only validated checklist for measuring the quality of observational studies of comparative effectiveness. ​Her diverse experience includes serving as a member of the PCORI Clinical Trials Methods Advisory Panel and a Standing Consultant to the National Football League Health & Safety Executive Committee.  She is a Fellow of both the Drug Information Association (DIA) and the International Society of Pharmacoepidemiology, and is an Adjunct Professor of Epidemiology at the Gillings School of Global Public Health at the University of North Carolina.  Her experience includes serving as CEO and Founder of Epidemiology Resources Inc., where she launched the journal, Epidemiology and led the New England Epidemiology Institute summer training program, and as a Senior Vice President at UnitedHealth’s Ingenix/i3 division.  In 2019 she received the DIA Global Inspire Award for Author of the Year for “Advancing a framework for regulatory use of real world evidence: When real is reliable,“ the most downloaded article in 2018 in Therapeutic Innovation & Regulatory Science.


Emmanuel Fombu
Global Strategy and Digital Innovation Leader
Johnson & Johnson


Karl Hick
Chief Digital & Information Officer
Takeda


Jim Scholefield
Chief Information & Digital Officer
Merck